Disciplined Equity Management Inc. Has $69,000 Position in Pfizer Inc. (NYSE:PFE)

Disciplined Equity Management Inc. raised its stake in Pfizer Inc. (NYSE:PFE) by 1,047.6% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 2,410 shares of the biopharmaceutical company’s stock after acquiring an additional 2,200 shares during the period. Disciplined Equity Management Inc.’s holdings in Pfizer were worth $69,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Wedge Capital Management L L P NC grew its holdings in Pfizer by 10.6% during the 3rd quarter. Wedge Capital Management L L P NC now owns 10,865 shares of the biopharmaceutical company’s stock worth $360,000 after acquiring an additional 1,044 shares during the period. Essex LLC increased its holdings in Pfizer by 16.4% in the third quarter. Essex LLC now owns 66,014 shares of the biopharmaceutical company’s stock worth $2,190,000 after purchasing an additional 9,288 shares in the last quarter. Capital Investment Advisors LLC lifted its stake in Pfizer by 5.9% in the third quarter. Capital Investment Advisors LLC now owns 718,558 shares of the biopharmaceutical company’s stock valued at $23,835,000 after buying an additional 40,233 shares during the period. Guidance Capital Inc. grew its position in shares of Pfizer by 9.9% during the 3rd quarter. Guidance Capital Inc. now owns 15,080 shares of the biopharmaceutical company’s stock worth $511,000 after buying an additional 1,358 shares during the period. Finally, Onyx Bridge Wealth Group LLC lifted its position in shares of Pfizer by 12.1% during the 3rd quarter. Onyx Bridge Wealth Group LLC now owns 17,201 shares of the biopharmaceutical company’s stock valued at $571,000 after acquiring an additional 1,852 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 0.2 %

Pfizer stock traded down $0.06 during midday trading on Wednesday, hitting $26.26. 24,501,011 shares of the stock were exchanged, compared to its average volume of 41,887,898. Pfizer Inc. has a 52-week low of $25.23 and a 52-week high of $40.37. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The business’s 50-day moving average price is $27.05 and its 200-day moving average price is $28.50. The stock has a market capitalization of $148.70 billion, a price-to-earnings ratio of 72.94, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company’s revenue was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.14 EPS. On average, research analysts expect that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.40%. Pfizer’s dividend payout ratio (DPR) is presently 466.67%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. Eleven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus target price of $36.33.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.